ஆண்டுவிழா ஆண்டு சந்தித்தல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஆண்டுவிழா ஆண்டு சந்தித்தல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஆண்டுவிழா ஆண்டு சந்தித்தல் Today - Breaking & Trending Today

IMV Inc. Announces First Quarter 2021 Financial and Operational Results and Expansion of its Clinical Pipeline

Press release content from Business Wire. The AP news staff was not involved in its creation.
IMV Inc. Announces First Quarter 2021 Financial and Operational Results and Expansion of its Clinical Pipeline
May 12, 2021 GMT
DARTMOUTH, Nova Scotia (BUSINESS WIRE) May 12, 2021
IMV Inc. (the “Company” or “IMV”) (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced its financial and operational results for the first quarter ended March 31, 2021.
“We remain focused on our commitment to provide effective and well-tolerated immunotherapies for patients with difficult-to-treat cancers. Clinical programs with our lead immunotherapy are progressing as expected, and we are pleased that maveropepimut-S will soon be evaluated in subjects with HR+/HER2- breast cancer, another unmet medical need,” announced Fred Ors, Chief Executive Officer at IMV. “We are reaching another milestone as our ....

United States , Wayne Pisano , Joanne Schindler , Mandy Sheldon , Michael Kalos , Eli Lilly , Kyle Kuvalanka , James Hall , Marc Jasmin , Yves Fradet , Delphine Davan , Society For Immunotherapy Of Cancer , Providence Cancer Institute In Portland , Fred Ors , Chief Executive Officer , Anniversary Annual Meeting , Recurrent Ovarian , Multiple Advanced Metastatic Solid , Providence Cancer Institute , Hormone Receptive , First In Human Dualt Cell Therapy , Based Vaccine Candidate Against , Chief Financial Officer , Chief Operating Officer , Goldfinch Bio , Vice President ,

IMV Inc. Announces Fourth Quarter and Full Year 2020 Financial and Operational Results

Press release content from Business Wire. The AP news staff was not involved in its creation.
IMV Inc. Announces Fourth Quarter and Full Year 2020 Financial and Operational Results
March 17, 2021 GMT
DARTMOUTH, Nova Scotia (BUSINESS WIRE) Mar 17, 2021
IMV Inc. (the “Company” or “IMV”) (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced its financial and operational results for the fourth quarter and year ended December 31, 2020.
“Notwithstanding the challenges everyone faced in 2020, IMV’s commitment to provide effective and well-tolerated immunotherapies to patients with hard-to-treat cancer resulted in significant progress on multiple fronts with our lead compound, Maveropepimut-S, and with other DPX-based candidates,” said Fred Ors, Chief Executive Officer at IMV Inc. “We see 2021 as a transformational year for IMV as we are advancing Maveropepimut-S in both relapse ....

United States , Bristol Meyers Squibb , Andrew Hall , Neil Berinstein , Relationsmarc Jasmin , American Society Of Hematology Annual Meeting , Society For Immunotherapy Of Cancer , Sunnybrook Health Sciences Center , Clinical Program Updates , Fred Ors , Chief Executive Officer , Rel Study , American Society , Hematology Annual , Anniversary Annual Meeting , Progression Free Survival , Recurrent Ovarian , Multiple Advanced Metastatic Solid , Hepatocellular Carcinoma , Based Vaccine Against , June At The Market , Chief Business Officer , Advanced Recurrent Ovarian , Investor Relationsmarc Jasmin , Senior Director , Investor Relations ,

NANOBIOTIX Reports Full Year 2020 Financial Results and Highlights Operational Progress

NANOBIOTIX Reports Full Year 2020 Financial Results and Highlights Operational Progress
Substantial progress in priority development pathway in head and neck cancer with clinical registration plan announced, Fast Track designation granted by US Food and Drug Administration, and new data from phase I dose expansion showing 83% objective response rate in primary lesion.
First clinical data reported phase I immuno-oncology trial showing conversion of anti-PD-1 non-responders to responders.
Extended global capital markets presence with a successful Nasdaq IPO that provided gross proceeds of €93.5 million ($113.3 million).
Cash, cash equivalents, and short-term investments were €119.2 million at December 31, 2020, supporting robust development plans into the second quarter of 2023. ....

United States , France General , United Kingdom , Brandon Owens , Kate Mcneil , Porter Novelli , Pierre Louis Germain , Communications Department , University Of Texas Md Anderson Cancer Center , Exchange Commission On , Society For Immunotherapy Of Cancer , French Financial Markets Authority Autorit , Investor Relations Department , Drug Administration , Research Development , American Association For Cancer Research , American Society For Radiation Oncology , Research Tax Credit , Fast Track , Laurent Levy , New Drug Application , American Society , Radiation Oncology , Anniversary Annual Meeting , Cancer Center , Nasdaq Global Select Market ,

Leap Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results

Leap Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., March 12, 2021 /PRNewswire/ Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2020.
2020 Leap Highlights:
Signed agreement with BeiGene, Ltd. for rights to Leap s anti-DKK1 antibody, DKN-01, in Asia (excluding Japan), Australia and New Zealand
Completed a $51.75 million public offering of common stock and pre-funded warrants to purchase common stock
Presented updated data from study of DKN-01 plus pembrolizumab in esophagogastric (EGC) cancer demonstrating positive outcomes in DKK1-high patients ....

New Zealand , United States , United Kingdom , Douglase Onsi , Heather Savelle , Society For Immunotherapy Of Cancer , Beigene Ltd , Biology Driving Research , American Association For Cancer Research , Securities Exchange , Leap Therapeutics Inc , Society Of Gynecologic Oncology , Leap Therapeutics , Orphan Drug Designation , Fast Track Designation , Chief Executive Officer , Beigene Announced First Patient Dosed , Gastroesophageal Junction , Presented Updated Data , Positive Outcomes , Anniversary Annual Meeting , Biomarker Selected Patients , American Association , Cancer Research , Virtual Special Conference , Endometrial Cancer ,

BioXcel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

Published: Mar 11, 2021
New Drug Application (“NDA”) submitted to the U.S. Food and Drug Administration (“FDA”) for BXCL501 for the acute treatment of schizophrenia and bipolar disorder related agitation
TRANQUILITY achieved primary and secondary endpoints with both doses of BXCL501; End of Phase 2 meeting with the FDA planned for Q2 2021
RELEASE trial on track to report topline results in Q1 2021
Topline results from two ongoing trials with BXCL701 in aggressive forms of prostate cancer and advanced solid tumors are expected in mid-2021
Company to host conference call today at 8:30 a.m. ET
NEW HAVEN, Conn., March 11, 2021 (GLOBE NEWSWIRE) BioXcel, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced its quarterly results for the fourth quarter and full year end ....

United States , Yale University , John Graziano , Julia Deutsch , Javier Rodriguez , Mary Coleman , June Bray , Vimal Mehta , American Psychiatric Association , Us Department Of Defense , Yale University Medical School , Company Nasdaq , Company Board Of Directors , Society For Immunotherapy Of Cancer , Research Programs , Bioxcel Therapeutics Inc , Drug Administration , Neuroscience Program , Oncology Program , Mental Health Awareness Month , Bioxcel Inc , New Drug Application , Chief Executive Officer , Full Year , Recent Highlights , Health Care System ,